Insmed Incorporated
INSMBiotechnology
$111.59+15.06%As of Oct 29vs prior close
- Market cap
- $24.4B
- P/E (TTM)
- –
- From 52W high
- −47.22%
- EPS (LTM)
- -$2.83
- Revenue (LTM)
- $1.5B
- Net margin
- -39.85%
- Dividend yield
- 0.00%
Nomior Score
40
Steady ProfileBottom 30% of the scored universe
Growth77
Quality52
Value46
Momentum10
Resilience41
Growth
$1.5Brevenue, LTM
FY16 $0LTM $1.5B
Connections
Revenue to profitQ3 FY26
The operating loss was 17% of revenue, narrower by 240 pts on a year.
Latest results
- Revenue outlook
- $1.35 Billion to $1.4 Billion
Insmed reported strong total revenue for the quarter, driven mainly by rapid U.S. growth of BRINSUPRI following its launch, while ARIKAYCE continued to grow, led by international markets. The company still posted a net loss for the quarter, and it raised the low end of its full-year revenue guidance for both BRINSUPRI and ARIKAYCE.
Who owns it
2funds, 2 tracked portfolios